MRCP UK

MRCP UK Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from MRCP UK, Digital creator, Hofuf.
(1)

ACE Inhibitors and ARBs: Adverse Effects comparision
26/09/2026

ACE Inhibitors and ARBs: Adverse Effects comparision

AF + HFrEF: RHYTHM CONTROL AND CATHETER ABLATION
26/09/2026

AF + HFrEF: RHYTHM CONTROL AND CATHETER ABLATION

Triptans: Class Contraindications and Medication-Specific Considerations
26/09/2026

Triptans: Class Contraindications and Medication-Specific Considerations

26/09/2026

A 58-year-old man with type 2 diabetes develops burning pain and tingling in both feet, worse at night. Examination demonstrates reduced distal sensation. He has ischemic heart disease with a prolonged QT interval, severe chronic kidney disease with eGFR 20 mL/min/1.73 m², and chronic liver disease. His vitamin B12 level is normal.

Which of the following is the most appropriate first-line treatment for his painful diabetic peripheral neuropathy?

A. Amitriptyline
B. Duloxetine
C. Vitamin B12
D. Pregabalin
E. Gabapentin

Multiple Sclerosis in Pregnancy: Treatment and Disease-Modifying Therapy
26/09/2026

Multiple Sclerosis in Pregnancy: Treatment and Disease-Modifying Therapy

Diagnostic Value of the Mentzer Index, RDW, and RBC Count in Microcytic Anemia
26/09/2026

Diagnostic Value of the Mentzer Index, RDW, and RBC Count in Microcytic Anemia

26/09/2026

A 32-year-old woman has moderate-to-severe extrarenal SLE with persistent skin and joint disease despite standard treatment. Which biologic acts by blocking the type I interferon receptor?

A. Belimumab
B. Rituximab
C. Anifrolumab
D. Tocilizumab
E. Abatacept

26/09/2026

A patient has moderately active extrarenal SLE despite hydroxychloroquine and conventional treatment. A biologic that inhibits B-cell activating factor is considered. Which drug has this mechanism?

A. Rituximab
B. Belimumab
C. Anifrolumab
D. Mycophenolate
E. Voclosporin

Obinutuzumab (Gazyva)Class: Glycoengineered, humanized type II anti-CD20 monoclonal antibody.Mechanism: Produces B-cell ...
26/09/2026

Obinutuzumab (Gazyva)

Class: Glycoengineered, humanized type II anti-CD20 monoclonal antibody.

Mechanism: Produces B-cell depletion through enhanced antibody-dependent cellular cytotoxicity/phagocytosis and strong direct B-cell death. Compared with rituximab, it can produce deeper and more sustained B-cell depletion.

Established indications: Primarily B-cell malignancies, including CLL and follicular lymphoma.

Nephrotic syndrome: Currently an off-label/emerging therapy, particularly of interest for frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS) and patients who relapse after or respond inadequately to rituximab.

Adult minimal-change disease: A 2026 report specifically described successful obinutuzumab monotherapy in adults with nephrotic syndrome and minimal-change lesions, but this remains early evidence

Orforglipron (Foundayo) received U.S. FDA approval on April 1, 2026Foundayo is an oral non-peptide GLP-1 receptor agonis...
26/09/2026

Orforglipron (Foundayo) received U.S. FDA approval on April 1, 2026

Foundayo is an oral non-peptide GLP-1 receptor agonist that does not need to be taken on an empty stomach.

FDA indication is chronic weight management in adults with obesity, or overweight plus at least one weight-related comorbidity, together with reduced-calorie diet and increased physical activity.

Address

Hofuf
181400

Website

Alerts

Be the first to know and let us send you an email when MRCP UK posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category